where Pen, penicillamine, is 3,3-dimethylcysteine. These analogs, which are conformationally restricted by virtue of cyclization I~Q the disulfide and are further rigidized due to the gem dimethyl substituents of the penicillamine residue(s), are notable for their high degree of selectivity for the delta opioid receptor over the mu opioid receptor. Within this series, the bis-penicillamine analogs display the highest selectivity yet reported for the delta receptor, while those analogs with a single penicillamine residue are less selective but are in general more potent. While some conformational differences are observed between members of this series, they appear to share a similar overall topography (4) . Of particular note is the similarity of conformation-dependent ' H n.m.r. parameters for the analogs, [D-C~S', ~-Pen']enkephalin and [D-Pen', ~-Pen']enkephalin (DPDPE) (4) , the former of which is more potent but less delta receptor selective than is the latter. These results suggest that the penicillamine 3-methyl groups at residue 2 lead to adverse steric interactions at delta and particularly at mu receptors and thus are responsible for the higher delta selectivity (and lower potency) of the bis-penicillamine analog. and (3S.3R)methylcysteine ((3R)Me-Dcjsteine) (Fig. I ) and utilized these for the synthesis of [ (~S ) M~-I I -C~S~, ~-P e n~] e n k ephalin and [(3R)Me-~-Cys', ~-Pen']enkephalin. Ebaluation ot' the opioid receptor binding profiles of these analogs and measurcmcnt of conformation-dependent ' H n.m.r. parameters indlcate that, indeed, each of the Pen' 3-methyl groups of [D-Pen', DPen'lenkephalin has a different effect on binding to mu and delta opioid receptors.
MATERIALS A N D METHODS

SJwthesis of ( 3 s ) M e -r K y s und (~R ) M~-L I -
Cys. (3S)Me-1,-cysteine and (3R)Me-~-cysteine were prepared by modifications of known routes or by extensions of standard methodologies.
(3S)Me-D-cysteine was prepared from allo-.V-Boc-O-tosyl-D-threonine methyl ester ((!/lo-D-threonine having been obtained from D-threonine by the procedure of Elliot (6)) by displacement of the tosylate moiety with potassium thiolacetate (7) followed b j deprotection. (3R)Me-D-cysteine was prepared in a similar fashion starting from thco-.V-Boc-O-tosyl-D-threonine methyl ester. The S,2 displacement of the tosylate by the thiolacetate anion in the first case proceeded without any elimination, 0-alkylation of thiolacetate, or S, I-type mechanism. Howeiw. considerable elimination occurred in thc latter as marked by the formation of methyl N-Boc-Z-amino crotonate. The elimination process was limited to ca. 40% by proper choice of solvent and temperature. Prior to their use in solid phase peptide synthesis, both (~R ) M~-D - Methyl cis-~phenyl-5-methyl-A~-oxazoline-4-carboxylate (5). Treatment of compound 2 with thionyl chloride at 0" for 2 h gave, after removal of excess thionyl chloride at 35" under reduced pressure, an oily residue. This residue was dissolved in chloroform and poured slowly with stirring into a 10% Na,CO, solution (care was taken to maintain a basic pH of the solution). The chloroform layer was separated, dried, and the solvent removed under reduced pressure to yield the title compound (87% yield) which solidified on standing. Crystallization of a small portion from petroleum ether gave a pure sample of 5, m.p. 75-76" [lit. 74-75" (6) ].
cysteine and (3S)Me-~-cysteine were converted to the S-p-methylbenzyl-N-Boc derivatives by standard methods.
~Threonine methyl ester hydrochloride (1). Dry HCl gas was passed through a suspension of D-threonine in methanol at 0" until the solid dissolved. The reaction was left overnight and the solvent was then removed under vacuum to give the title compound as a white solid in 94% yield. The ester was used without further purification.
N-Benzoyl-Dthreonine methyl ester (2). The methyl ester 1 was benzoylated according to the procedure of Elliot (6) by adding benzoyl chloride dropwise to ester 1 dissolved in dioxane-water while maintaining the pH at 8.8-9.0 with 5~ NaOH. After removal of the dioxane, the aqueous phase was extracted with ethyl acetate. After drying over MgSO,, the ethyl acetate was removed to afford 2, which was recrystallized from benzene to give a 65% yield of pure 2, m.p. 93-94".
N-Boc-Dthreonine methyl ester (3). The methyl ester 1 was dissolved in a Na,CO, solution (dioxane/water. 2:l) at 0" and treated with di-tert.-butyl dicarbonate according to standard literature protocol (8) to give the title threonine derivative in 86% yield as an oil which was used, without further purification, in the next step.
N-Boc-0-tosyl-Dthreonine methyl ester (4).
To compound 3 dissolved in pyridine and cooled to 0" was added solid tosyl chloride in portions. The reaction was allowed to stand overnight and was then poured into ice water. The oil that formed was extracted with diethyl ether. The combined ether fractions were washed with 0 . 5~ HCl, water, and saturated Na, CO,. Evaporation of the diethyl ether, after drying over MgS04, afforded crude 4 in 80% yield. The crude tosylate was purified on silica gel with first 9:l and then 7: 3, hexane:ethyl acetate. Evaporation of the fractions containing the tosylate gave 70% of 4 as a clear. viscous oil.
allo-DThreonine (6). Crude 5 was hydrolyzed by heating in 6~ HCl at 95" for 5 h followed by cooling to room temperature, filtering off the benzoic acid precipitate, and evaporating the aqueous filtrate. The resulting syrup was purified by cation exchange chromotography to give allo-D-threonine in 69% yield based on 2. M.p. 274-276" (lit. 276280" (7)
allo-N-Boc-0-tosyl-Dthreonine methyl ester (7). Compound 7, also an oil, was prepared from 6 by the methods described above for the preparation of the diastereomer, 4.
(3S)Me-D-cysteine (8). Compound 8 was prepared in 5 1 YO overall yield by treatment of 7 with potassium thiolacetate in DMF overnight at room temperature followed by hydrolysis of the crude S-acetylamino acid product in refluxing 1 2~ HCI for 5 h (7) to give the crude amino acid in 75% yield. The target compound was further purified via cation exchange chromotography to give
(c 1, 1 N HC1)(9)}.
[El: 1 N HC1 ) (9)).
S-p-Methylben;j+ (3R) Me-o-cjgsteine (10). Amino acid 9 was treated with sodium-liquid ammonia to give the sodium salt of the thio amino acid which was alkylated with pmethylbenzyl bromide directly in the liquid ammonia solution. Evaporation of the ammonia gave the S-protected amino acid which was purified by crystallization from acetic acid-water to give the title compound in 55% yield. M.p. 185-187", [r]: = 47.5" (c 1, 0.1 N HCI).
S-p-Methylbenzyl-(3S) Me-o-cysteine (1 1). Amino acid 8 was aklylated with p-methylbenzyl bromide to give the title compound in 60% yield. M.p. 177-178", [2]2 = -83.9"(c I , 1 N HCl).
N-Boc-S-p-Methylbenzyl-(3R) Me-Pcysteine (12). The S-protected cysteine analog 10 was converted into the N-Boc derivative, an oil, by standard procedures, described above for 3, in 63% yield. (2,3) . Purification was effected by semipreparative HPLC on a Vydac 218TP C-18 column (2.5cm x 22cm) with the solvent system 0.1% TFA in H20/0.1% TFA in acetonitrile, using a 0-50% gradient of organic component. Purity of both peptides was greater than 99% as assessed by analytical HPLC monitored at both 280 nm and 230 nm. Opioid receptor bindiug assays. Selective, radioactive opioid peptides were used to label mu versus delta opioid receptors in brain sections and to evaluate binding profiles. Male Sprague-Dawley rats were sacrificed by decapitation and their brains were quickly removed and frozen in liquid isopentane ( -30") for 30 s. Frozen brains were sectioned in a bright Cryostut (25pm) and thawmounted on precleaned, gelatin-coated microscope slides. The brain sections were then dried overnight at 4" under reduced pressure in a glass desiccator and stored at -80". The slide-mounted sections were gradually brought to room temperature immediately prior to use, and were incubated with 200 pL of ['Hlligand in chambers designed to maintain ambient temperature (25") and humidity (6&8O%). The slides were incubated for 60min, drained, and washed in four consecutive 250-mL washes of 50 mM Tris (pH 7.6, 4"). Table 1 (4) and differences in opioid receptor binding behavior for these analogs can be attributed to steric interactions between the Pen2 3-methyl groups and the receptor binding sites. However, the asymmetrically substituted 3 -M e -o -c~~' analogs might assume different conformations. In order to assess the relative contributions of conformational differences and steric interactions on the opioid receptor binding 0 . 9 n~ for t3H]DAG0 and 7 . 5 n~ for [3H]DPDPE. Following the Tris washes, all slides were rinsed with 250 mL distilled water (4') and quickly dried with a portable hair dryer. Nonspecific binding was evaluated by treating a parallel set of slides with the same concentrations of [3H]ligand with a 1 .DM final concentration of an unlabeled competitor: levorphanol to displace [3H]DAG0 and either Tyr-D-Ser-Gly-Phe-Leu-Thr (DSLET) (1 1) or DPDPE to displace [3H]DPDPE. Test compounds were evaluated over the concentration range 0.1 nM to 1 0~~. The binding was quantified by placing the brain sections into scintillation vials containing 10 mL scintillant and vigorously shaking for 30 min. Each data point is an average of a minimum of two brain sections and IC,, values were calculated by using log-logit plots. Table 1 Binding studies were performed on rat brain slices incubated at 25' in 5 0 m~ Tris buffer at pH 7.6. Radioligand concentrations were 7.5 n M for the dclta selective ligand [jH]DPDPE and 0 . 9 n~ for the mu selective ligand [jH]DAGO. *Values reported are IC,,, f SFM (standard error of the mean). E = enkephalin.
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properties of these analogs, conformationdependent 'H n.m.r. parameters were measured and are compared to those previously reported for [D-Pen' , ~-Pen']enkephalin and [D-Cys', ~-Pen']enkephalin (4) in Table 2 . As can be seen from Table 2 As is also apparent in Table 2 Pen'lenkephalin apparently has no effect on mu receptor binding and the reduced mu re-
